Results of the CORTICO-COP trial that administering systemic corticosteroid prednisolone only on days when blood eosinophil count was at least 0.3 x 109 cells/L in patients with chronic obstructive pulmonary disease (COPD) significantly reduced systemic corticosteroid exposure; although this strategy did not confer a benefit in terms of the number of days alive and out of hospital.
Dr Pradeesh Sivapalan (University of Copenhagen, Denmark) presented the research in a late-breaking clinical trial session, noting that the work was being simultaneously published in The Lancet Respiratory Medicine [1,2]. Corticosteroids are frequently used in the treatment of acute COPD exacerbations. However, the use of systemic corticosteroids is not without risks. As such, strategies to limit systemic corticosteroid exposure are needed. In this multicentre randomised controlled trial, 318 patients age 4...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Letter from the Editor and Biography Next Article
Stem Cell Therapy in Acute Respiratory Distress Syndrome Improves 28-day Mortality »
Table of Contents: ATS 2019
Treatable Traits in Chronic Inflammatory Airway Disease: Back to Basics
Critical Care Medicine
Pulmonary Vascular Disease and Interstitial Lung Disease
Paediatric Pulmonary Medicine
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.